Is Shingrix a Live Vaccine?
No, Shingrix is not a live vaccine. It uses a recombinant glycoprotein E antigen from the varicella-zoster virus combined with an AS01B adjuvant system to stimulate an immune response without containing live virus.[1]
How Does Shingrix Differ from Zostavax?
Shingrix replaced Zostavax, which was a live attenuated vaccine using a weakened form of the varicella-zoster virus. Zostavax carried risks like vaccine-related shingles in immunocompromised patients, leading to its discontinuation in the US in 2020. Shingrix avoids these issues due to its non-live formulation.[1][2]
Who Can Safely Get Shingrix?
Shingrix is approved for adults 50 and older, and immunocompromised adults 19 and older, including those with weakened immune systems. Its non-live status makes it suitable for people who cannot receive live vaccines, such as transplant recipients or those on immunosuppressive therapy.[1][3]
What Are Common Side Effects?
Reactions include pain, redness, or swelling at the injection site, muscle pain, fatigue, headache, shivering, fever, and nausea. These typically last 2-3 days and are more common than with live vaccines like Zostavax.[1][3]
Shingrix Dosing Schedule
Two doses are given 2-6 months apart. Effectiveness reaches over 90% against shingles and postherpetic neuralgia in adults 50+, with sustained protection up to 10 years.[1][2]
[1]: CDC - Shingrix VIS
[2]: FDA Shingrix Prescribing Information
[3]: CDC Shingrix Recommendations